Open Access
Issue
J Oral Med Oral Surg
Volume 24, Number 1, Janvier 2018
Page(s) 11 - 21
Section Revue de la littérature / Literature review
DOI https://doi.org/10.1051/mbcb/2017030
Published online 25 May 2018
  1. Poulain B, Lonchamp E, Jover E, Popoff MR, Molgó J. Mechanisme d'action de la toxine botulique. Ann Dermatol Vénéréologie 2009;136:S73–S76. [CrossRef] [Google Scholar]
  2. Wenzel R. Pharmacology of botulinum neurotoxin serotype A. Am J Health Syst Pharm AJHP 2004;61:S5–S10. [Google Scholar]
  3. Dorizas A, Krueger N, Sadick NS. Aesthetic uses of the botulinum toxin. Dermatol Clin 2014;32:23–36. [CrossRef] [Google Scholar]
  4. Frevert J. Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products. Drugs RD 2015;15:1–9. [CrossRef] [Google Scholar]
  5. Lew HL, Lee E, Castaneda A, Klima R, Date E. Therapeutic use of botulinum toxin type A in treating neck and upper-back pain of myofascial origin: a pilot study. Arch Phys Med Rehabil 2008;89:75–80. [CrossRef] [PubMed] [Google Scholar]
  6. Qerama E, Fuglsang-Frederiksen A, Kasch H, Bach FW, Jensen TS. A double-blind, controlled study of botulinum toxin A in chronic myofascial pain. Neurology 2006;67:241–245. [CrossRef] [PubMed] [Google Scholar]
  7. Ernberg M, Hedenberg-Magnusson B, List T, Svensson P. Efficacy of botulinum toxin type A for treatment of persistent myofascial TMD pain: a randomized, controlled, double-blind multicenter study. Pain 2011;152:1988–1996. [CrossRef] [PubMed] [Google Scholar]
  8. Ojala T, Arokoski J-P-A., Partanen J. The effect of small doses of botulinum toxin a on neck-shoulder myofascial pain syndrome: a double-blind, randomized, and controlled crossover trial. Clin J Pain 2006;22:90–96. [CrossRef] [PubMed] [Google Scholar]
  9. Göbel H, Heinze A, Reichel G, Hefter H, Benecke R. Dysport myofascial pain study group. Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: results from a randomized double-blind placebo-controlled multicentre study. Pain 2006;125:82–88. [Google Scholar]
  10. Benecke R, Heinze A, Reichel G, Hefter H, Göbel H. Dysport myofascial pain study group. Botulinum type A toxin complex for the relief of upper back myofascial pain syndrome: how do fixed-location injections compare with trigger point-focused injections? Pain Med 2011;12:1607–1614. [Google Scholar]
  11. Guarda-Nardini L, Manfredini D, Salamone M, Salmaso L, Tonello S, Ferronato G. Efficacy of botulinum toxin in treating myofascial pain in bruxers: a controlled placebo pilot study. Cranio J Craniomandib Pract 2008;26:126–135. [Google Scholar]
  12. Lee S-J., McCall W-D., Kim Y-U., Chung S-C., Chung J-W. Effect of botulinum toxin injection on nocturnal bruxism: a randomized controlled trial. Am J Phys Med Rehabil Assoc Acad Physiatr 2010;89:16–23. [CrossRef] [Google Scholar]
  13. Fedorowicz Z, van Zuuren E, Schoones J. Botulinum toxin for masseter hypertrophy. Cochrane Database Syst Rev 2013;9:C D007510. [Google Scholar]
  14. Fietzek UM, Kossmehl P, Barthels A, Ebersbach G, Zynda B, Wissel J. Botulinum toxin B increases mouth opening in patients with spastic trismus. Eur J Neurol 2009;16:1299–1304. [CrossRef] [PubMed] [Google Scholar]
  15. Guarda-Nardini L, Stecco A, Stecco C, Masiero S, Manfredini D. Myofascial pain of the jaw muscles: comparison of short-term effectiveness of botulinum toxin injections and fascial manipulation technique. Cranio J Craniomandib Pract 2012;30:95–102. [Google Scholar]
  16. Kurtoglu C, Gur O-K., Kurkcu M, Sertdemir Y, Guler-Uysal F, Uysal H. Effect of botulinum toxin-A in myofascial pain patients with or without functional disc displacement. J Oral Maxillofac Surg 2008;66:1644–1651. [CrossRef] [PubMed] [Google Scholar]
  17. Denglehem C, Maes J-M., Raoul G, Ferri J. Toxine botulinique de type a: traitement antalgique des dysfonctions de l'appareil manducateur. Rev Stomatol Chir Maxillofac 2012;113:27–31. [CrossRef] [PubMed] [Google Scholar]
  18. Sidebottom A-J., Patel A-A., Amin J. Botulinum injection for the management of myofascial pain in the masticatory muscles. A prospective outcome study. Br J Oral Maxillofac Surg 2013;51:199–205. [CrossRef] [Google Scholar]
  19. Polo M. Botulinum toxin type A in the treatment of excessive gingival display. Am J Orthod Dentofacial Orthop 2005;127:214–218. [CrossRef] [PubMed] [Google Scholar]
  20. Suber J-S, Dinh T-P, Prince M-D, Smith P-D. OnabotulinumtoxinA for the treatment of a gummy smile. Aesthetic Surg J Am Soc Aesthetic Plast Surg 2014;34:432–437. [CrossRef] [Google Scholar]
  21. Reid SM, Johnstone BR, Westbury C, Rawicki B, Reddihough DS. Randomized trial of botulinum toxin injections into the salivary glands to reduce drooling in children with neurological disorders. Dev Med Child Neurol 2008;50:123–128. [CrossRef] [PubMed] [Google Scholar]
  22. Alrefai AH, Aburahma SK, Khader YS. Treatment of sialorrhea in children with cerebral palsy: a double-blind placebo controlled trial. Clin Neurol Neurosurg 2009;111:79–82. [CrossRef] [PubMed] [Google Scholar]
  23. Jongerius P-H, van den HF, van Limbeek J, Gabreëls F-J, van Hulst K, Rotteveel J-J. Effect of botulinum toxin in the treatment of drooling: a controlled clinical trial. Pediatrics 2004;114:620–627. [CrossRef] [PubMed] [Google Scholar]
  24. Suskind D-L., Tilton A. Clinical study of botulinum-A toxin in the treatment of sialorrhea in children with cerebral palsy. The Laryngoscope 2002;112:73–81. [CrossRef] [PubMed] [Google Scholar]
  25. Basciani M, Di Rienzo F, Fontana A, Copetti M, Pellegrini F, Intiso D. Botulinum toxin type B for sialorrhoea in children with cerebral palsy: a randomized trial comparing three doses. Dev Med Child Neurol 2011;53:559–564. [CrossRef] [PubMed] [Google Scholar]
  26. Mancini F, Zangaglia R, Cristina S, Sommaruga M-G., Martignoni E, Nappi G, et al. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord 2003;18:685–688. [CrossRef] [PubMed] [Google Scholar]
  27. Guidubaldi A, Fasano A, Ialongo T, Piano C, Pompili M, Mascianà R, et al. Botulinum toxin A versus B in sialorrhea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's disease. Off J Mov Disord Soc 2011;26:313–319. [CrossRef] [Google Scholar]
  28. Chinnapongse R, Gullo K, Nemeth P, Zhang Y, Griggs L. Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: a prospective double-blind trial. Mov Disord 2012;27:219–226. [CrossRef] [PubMed] [Google Scholar]
  29. Dogu O, Apaydin D, Sevim S, Talas D, Aral M. Ultrasound-guided versus blind intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson's disease. Clin Neurol Neurosurg 2004;106:93–96. [CrossRef] [PubMed] [Google Scholar]
  30. Lipp A, Trottenberg T, Schink T, Kupsch A, Arnold G. A randomized trial of botulinum toxin A for treatment of drooling. Neurology 2003;61:1279–1281. [CrossRef] [PubMed] [Google Scholar]
  31. Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo M-G. Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord 2006;21:704–707. [Google Scholar]
  32. Kalf J-G., Smit A-M., Bloem B-R., Zwarts M-J., Mulleners W-M., Munneke M. Botulinum toxin A for drooling in Parkinson's disease: a pilot study to compare submandibular to parotid gland injections. Parkinsonism Relat Disord 2007;13:532–534. [CrossRef] [PubMed] [Google Scholar]
  33. Mazlan M, Rajasegaran S, Engkasan J-P, Nawawi O, Goh K-J, Freddy S-J. A double-blind randomized controlled trial investigating the most efficacious dose of Botulinum toxin-A for Sialorrhea treatment in Asian adults with neurological diseases. Toxins 2015;7:3758–3770. [CrossRef] [PubMed] [Google Scholar]
  34. Arnaud S, Batifol D, Goudot P, Yachouh J. Prise en chage non-surgical des plaies de la glande parotide et du canal de stenon: intérêt de la toxine botulique. Ann Chir Plast Esthét 2008;53:36–40. [CrossRef] [Google Scholar]
  35. Nolte D, Gollmitzer I, Loeffelbein DJ, Hölzle F, Wolff K-D. Botulinum toxin for treatment of gustatory sweating. A prospective randomized study. Mund- Kiefer- Gesichtschirurgie MKG 2004;8:369–375. [CrossRef] [Google Scholar]
  36. Majid OW. Clinical use of botulinum toxins in oral and maxillofacial surgery. Int J Oral Maxillofac Surg 2010;39:197–207. [CrossRef] [PubMed] [Google Scholar]
  37. Chassagne J-F, Cassier S, Simon E, Wang C, Chassagne S, Stricker C, et al. Limitation d'ouverture de bouche. EMC chirurgie orale et maxillo-faciale. Elsevier, 2009. [Google Scholar]
  38. Mazzuco R, Hexsel D. Gummy smile and botulinum toxin: a new approach based on the gingival exposure area. J Am Acad Dermatol 2010;63:1042–1051. [CrossRef] [PubMed] [Google Scholar]
  39. Devoize L, Dallel R. Salivation. In: EMC stomatologie. Paris: Elsevier Masson SAS, 2011. [Google Scholar]
  40. Monnier G, Tatu L, Parratte B, Cosson A, Michel F, Metton G. Hypersialorrhée, hypersudation et toxine botulique. Ann Réadapt Médecine Phys Rev Sci Société Fr Rééduc Fonct Réadapt Médecine Phys 2003;46:338–345. [Google Scholar]
  41. Friedman A, Potulska A. Quantitative assessment of parkinsonian sialorrhea and results of treatment with botulinum toxin. Parkinsonism Relat Disord 2001;7:329–332. [CrossRef] [PubMed] [Google Scholar]
  42. Meningaud J-P., Pitak-Arnnop P, Chikhani L, Bertrand J-C. Drooling of saliva: a review of the etiology and management options. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;101:48–57. [CrossRef] [PubMed] [Google Scholar]
  43. Marchese-Ragona R, Marioni G, Restivo D-A., Staffieri A. The role of botulinum toxin in postparotidectomy fistula treatment. A technical note. Am J Otolaryngol 2005;27:221–224. [CrossRef] [Google Scholar]
  44. Laccourreye O, Muscatello L, Gutierrez-Fonseca R, Seckin S, Brasnu D, Bonan B. Syndrome de frey sévère post-parotidestomie: traitement par la neuro-toxine botulique de type A. Ann Oto-Laryngol Chir Cervico Faciale 1999;116:137–142. [Google Scholar]
  45. Moltrecht M, Michel O. The woman behind Frey's syndrome: the tragic life of Lucja Frey. The Laryngoscope 2004;114:2205–2209. [CrossRef] [PubMed] [Google Scholar]
  46. Cantarella G, Berlusconi A, Mele V, Cogiamanian F, Barbieri S. Treatment of Frey's syndrome with botulinum toxin type B. Otolaryngol Head Neck Surg 2010;143:214–218. [CrossRef] [PubMed] [Google Scholar]
  47. Ng S, Torjek C, Hovan A. Management of Frey syndrome using botulinum neurotoxin: a case report. ET J 2009;75:651–654. [Google Scholar]
  48. Lobbezoo F, Ahlberg J, Glaros AG, Kato T, Koyano K, Lavigne GJ et al. Bruxism defined and graded: an international consensus. J Oral Rehabil 2013;40:2–4. [CrossRef] [PubMed] [Google Scholar]
  49. Baş B, Ozan B, Muğlali M, Celebi N. Treatment of Masseteric hypertrophy with Botulinum toxin: a report of two cases. Med. Oral Patol. Oral Y Cirugía Bucal 2010;15:e649–e652. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.